This correlation could indicate that the activation of NRF2 is hampered by Arg-DPRs in ALS patients, helping to explain the results recently disclosed from a clinical trial aiming to evaluate the safety and efficacy of DMF in ALS [50]. This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.